Unmasking targets of antitumor immunity via high-throughput antigen profiling

- Identity of antigens recognized during anti-tumor immune responses is largely unknown.
- Advances in sequencing and in silico analysis have revealed non-shared antigens.
- Antigen discovery is critical in determining targets during anti-tumor immune responses.
- Validation is essential since immune cells recognize few in silico candidate antigens.
- Neoantigens can be exploited to design personalized cancer vaccines.